NPI 1124197512: Open Payments
NPI 1124197512. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$597 in 16 payments from 14 companies in 2025. Trend: 2023 $406 · 2024 $790 · 2025 $597
Food & beverage: $498Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 2 | $143 |
| PFIZER INC. | 2 | $112 |
| SEAGEN INC. | 1 | $99 |
| EMD Serono, Inc. | 1 | $34 |
| ABBVIE INC. | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| ARRAY BIOPHARMA INC | 1 | $23 |
| Gilead Sciences, Inc. | 1 | $22 |
Products named: RYBREVANT, XTANDI, ELAHERE, Orserdu, QINLOCK, Lenvima, LORBRENA, Trodelvy.
